May 2026
LSD
What May 2026's 9 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research on LSD in May 2026 found that it reverses aging- and neurodegeneration-associated brain transcriptional programs in rodents, prolongs brain-stimulation-induced neural activity changes, and persistently reduces affective pain processing in rats. In a clinical trial, LSD treatment was associated with white matter microstructural changes that correlated with antidepressant effects in major depression. However, an observational study linked LSD use to higher insomnia severity among young adult cannabis consumers, and a review highlighted the lack of systematic evaluation of pharmacological interventions for adverse psychedelic experiences.
Confidence in the evidence
Low-Moderate- The evidence includes a mix of preclinical studies (rodent models) and one clinical trial with 35 patients, limiting generalizability.
- The clinical trial (article_id 27868) is a secondary analysis of an RCT with a moderate sample size, but lacks a placebo control for the LSD groups.
- Results are consistent across preclinical studies showing neuroplastic and pain-reducing effects, but the observational study on insomnia (article_id 28027) shows a conflicting direction.
- Several studies (e.g., article_id 28023, 27829) are reviews or dissertations that do not provide original empirical data on LSD specifically.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Lysergic acid diethylamide reverses aging- and neurodegeneration-associated brain transcriptional programs 2026 | preclinical experimental | — | Supports | LSD induces gene expression patterns strongly anti-correlated with aging and neurodegeneration programs in the human prefrontal cortex, as shown by cross-species transcriptomic analyses. |
| Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes. 2026 | preclinical experimental | — | Supports | LSD pretreatment resulted in larger and longer-lasting changes in brain activity following electrical stimulation of the infralimbic cortex compared to saline. |
| IDENTIFYING THE NEUROPHYSIOLOGICAL MECHANISMS UNDERLYING THE POTENTIAL THERAPEUTIC EFFECTS OF PSYCHEDELIC COMPOUNDS 2026 | theoretical/review | — | Unclear | This dissertation describes that all tested psychedelic compounds are agonists at the 5-HT2A receptor and identifies a population of 5-HT2AR neurons in the prefrontal cortex, but does not report specific findings on LSD. |
| LSD persistently disrupts affective pain processing. 2026 | preclinical experimental | — | Supports | A single dose of LSD persistently reduces pain affect in rats, an effect recapitulated by local administration in the anterior cingulate cortex, and suppresses stimulus-evoked nociceptive responses. |
| Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment 2026 | RCT (secondary analysis) | 35 | Supports | LSD treatment (moderate-to-high dose) was associated with increased fractional anisotropy in white matter tracts, and these changes correlated with improvements in depressive symptoms at 2, 6, and 12 weeks. |
| 0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study 2026 | observational | 100 | Opposes | Among daily cannabis consumers, LSD use was associated with a higher prevalence of moderate-to-severe clinical insomnia (17.7%) compared to non-LSD users (0.0%, p=0.006). |
| Effects of psychedelic use on authoritarian attitudes revisited. 2026 | observational and RCT | — | No effect | Across three studies, psychedelic use (including LSD) showed no significant changes in authoritarian attitudes, contrary to previous research. |
| Trip killers: Addressing a critical knowledge gap in psychedelic research. 2026 | review | — | Unclear | This review identifies candidate medications for terminating adverse psychedelic experiences but notes a critical knowledge gap and lack of systematic evaluation of pharmacological interventions. |
| Associations between psychedelic use and migraine history in Swedish twins. 2026 | observational (cross-sectional) | 50726 | Supports | Psychedelic use (including LSD) was associated with lower odds of migraine history in monozygotic twins (within-pair aOR = 0.38, p = 0.008), though no significant association was observed in female-only models. |
LSD induces gene expression patterns strongly anti-correlated with aging and neurodegeneration programs in the human prefrontal cortex, as shown by cross-species transcriptomic analyses.
preclinical experimental
LSD pretreatment resulted in larger and longer-lasting changes in brain activity following electrical stimulation of the infralimbic cortex compared to saline.
preclinical experimental
This dissertation describes that all tested psychedelic compounds are agonists at the 5-HT2A receptor and identifies a population of 5-HT2AR neurons in the prefrontal cortex, but does not report specific findings on LSD.
theoretical/review
A single dose of LSD persistently reduces pain affect in rats, an effect recapitulated by local administration in the anterior cingulate cortex, and suppresses stimulus-evoked nociceptive responses.
preclinical experimental
LSD treatment (moderate-to-high dose) was associated with increased fractional anisotropy in white matter tracts, and these changes correlated with improvements in depressive symptoms at 2, 6, and 12 weeks.
RCT (secondary analysis) · Sample size: 35
Among daily cannabis consumers, LSD use was associated with a higher prevalence of moderate-to-severe clinical insomnia (17.7%) compared to non-LSD users (0.0%, p=0.006).
observational · Sample size: 100
Across three studies, psychedelic use (including LSD) showed no significant changes in authoritarian attitudes, contrary to previous research.
observational and RCT
This review identifies candidate medications for terminating adverse psychedelic experiences but notes a critical knowledge gap and lack of systematic evaluation of pharmacological interventions.
review
Psychedelic use (including LSD) was associated with lower odds of migraine history in monozygotic twins (within-pair aOR = 0.38, p = 0.008), though no significant association was observed in female-only models.
observational (cross-sectional) · Sample size: 50726
Points of agreement
- Preclinical studies consistently show that LSD induces neuroplastic changes and alters brain activity in rodents.
- LSD shows potential therapeutic effects on pain and depression in animal models and a clinical trial.
- LSD's effects are mediated through the 5-HT2A receptor and involve the prefrontal cortex.
Conflicts
- LSD was associated with reduced migraine history in a large twin study but linked to higher insomnia severity in a small observational study of cannabis consumers.
- The clinical trial found positive effects on depression, while the observational study on insomnia suggests potential negative effects on sleep.
- The review on trip killers highlights a lack of systematic evidence, contrasting with the positive findings from other studies.
Gaps
- Durability of LSD's effects beyond 12 weeks is not addressed in the clinical trial.
- Blinding and placebo control are lacking in the clinical trial's secondary analysis of white matter changes.
- Populations studied are limited: mostly rodents, patients with MDD, or specific subgroups (cannabis users, twins).
- Dose-response relationships and optimal dosing for therapeutic effects are not systematically explored.
- The mechanisms underlying the association between LSD and insomnia are not investigated.